Anti-IL2 receptor gamma antigen-binding proteins
AssigneeRegeneron Pharmaceuticals, Inc.
InventorsJamie M. Orengo, Andrew J. Murphy
Life of this patent
Estimating the term…
Abstract
The present invention provides antibodies and antigen-binding fragments (e.g., human antibodies) that bind specifically to human IL2 receptor gamma (IL2Rγ). Methods for treating or preventing diseases mediated by IL2Rγ (e.g., graft vs host disease) using the antibodies and fragments are also provided along with methods of making the antibodies and fragments.
Claims23
An isolated antibody or antigen-binding fragment thereof that specifically binds to interleukin-2 receptor gamma (IL2Rγ) or an antigenic fragment thereof, wherein the antibody or antigen-binding fragment thereof comprises:
- a heavy chain immunoglobulin or variable region thereof comprising a CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO:
- 347, a CDR-H2 comprising the amino acid sequence set forth in SEQ ID NO:
- 349, and a CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO:
- 351;
- and a light chain immunoglobulin or variable region thereof comprising a CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO:
- 72, a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO:
- 54, and a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO:
- 355.
An isolated antibody or antigen-binding fragment thereof that specifically binds to interleukin-2 receptor gamma (IL2Rγ) or an antigenic fragment thereof, wherein the antibody or antigen-binding fragment comprises:
- a heavy chain variable region that comprises the amino acid sequence set forth in SEQ ID NO:
- 345;
- and a light chain variable region that comprises the amino acid sequence set forth in SEQ ID NO:
- 353.
A polypeptide comprising:
- (a) CDR-H1, CDR-H2, and CDR-H3 of a heavy chain variable region that comprises the amino acid sequence set forth in SEQ ID NO:
- 345;
- and
- (b) CDR-L1, CDR-L2, and CDR-L3 of a light chain variable region that comprises the amino acid sequence set forth in SEQ ID NO:
- 353.
Dependencies are inferred from the claim text.